2024
Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu W, Yu G, Chiasserini C, Somani N, Holzwarth K, King B. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 583-593. PMID: 38391212, DOI: 10.1111/jdv.19665.Peer-Reviewed Original ResearchConceptsSafety of baricitinibSALT scoreSevere alopecia areataPhase 3 trialAlopecia areataSevere AATract infectionsFrequent treatment-emergent adverse eventsMixed respondersWeeks of continuous therapyTreatment-emergent adverse eventsCreatine phosphokinase increaseUpper respiratory tract infectionUrinary tract infectionMaintenance of efficacyProportion of patientsRespiratory tract infectionsTreated with 2 mgLong-term efficacyLong-term treatmentJanus kinase inhibitorsJanus kinaseEyelash regrowthWeek-52Treatment discontinuation
2021
It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalis
Peterson D, Craiglow BG, Mesinkovska NA, Ko J, Senna MM, King B. It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalis. Journal Of The American Academy Of Dermatology 2021, 87: e149-e151. PMID: 34678234, DOI: 10.1016/j.jaad.2021.09.056.Peer-Reviewed Original Research
2020
Development of the Scalp Hair Assessment PRO™ measure for alopecia areata
Wyrwich K, Kitchen H, Knight S, Aldhouse N, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King B. Development of the Scalp Hair Assessment PRO™ measure for alopecia areata. British Journal Of Dermatology 2020, 183: 1065-1072. PMID: 32163589, PMCID: PMC7754291, DOI: 10.1111/bjd.19024.Peer-Reviewed Original ResearchConceptsScalp hair lossHair lossPRO measuresValid patient-reported outcome measurePatient-reported outcome measuresAlopecia areata treatmentInvestigator's Global AssessmentHair regrowthAlopecia areataTreatment successOutcome measuresQualitative semistructured interviewsPatientsGlobal assessmentAA treatmentClinical expertsScalp hairSemistructured interviewsTreatmentAreataResponse scaleSymptomsBaselineAAMeasuresThe Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
Wyrwich K, Kitchen H, Knight S, Aldhouse N, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King B. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. British Journal Of Dermatology 2020, 183: 702-709. PMID: 31970750, PMCID: PMC7586961, DOI: 10.1111/bjd.18883.Peer-Reviewed Original ResearchConceptsInvestigator's Global AssessmentScalp hair lossAlopecia areataTreatment successGlobal assessmentAlopecia ToolClinical trialsClinician's perspectiveScalp hairTreatment studiesInvestigator's Global Assessment (IGA) scaleSigns/symptomsScalp hair growthGlobal Assessment ScaleMost patientsAdolescent patientsHair regrowthClinical evaluationExpert dermatologistsSuccessful treatmentClinical consensusTreatment outcomesPatient insightTreatment responseAdditional clinicians
2019
Combination tofacitinib and oral minoxidil treatment for severe alopecia areata
Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. Journal Of The American Academy Of Dermatology 2019, 85: 743-745. PMID: 31499158, DOI: 10.1016/j.jaad.2019.08.080.Peer-Reviewed Original ResearchIL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
Ortolan LS, Kim S, Crotts S, Liu LY, Craiglow BG, Wambier C, Paschoal RS, King BA, Jabbari A. IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. Journal Of Allergy And Clinical Immunology 2019, 144: 1731-1734.e1. PMID: 31470035, PMCID: PMC6900443, DOI: 10.1016/j.jaci.2019.08.014.Peer-Reviewed Original Research
2016
Tofacitinib for the treatment of alopecia areata and variants in adolescents
Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Journal Of The American Academy Of Dermatology 2016, 76: 29-32. PMID: 27816292, DOI: 10.1016/j.jaad.2016.09.006.Peer-Reviewed Original ResearchConceptsAlopecia areataAdverse eventsAdolescent patientsTreatment of AASignificant hair regrowthUse of tofacitinibMonths of treatmentProspective clinical trialsMedian percent changeJanus kinase inhibitorSeverity of diseaseReview of systemsSALT scoreAlopecia ToolLaboratory monitoringPhysical examinationHair regrowthClinical trialsEffective therapyPromising therapyRetrospective natureTofacitinibControl groupPatientsPercent changeTofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. Journal Of The American Academy Of Dermatology 2016, 76: 22-28. PMID: 27816293, DOI: 10.1016/j.jaad.2016.09.007.Peer-Reviewed Original ResearchConceptsSevere alopecia areataAlopecia areataAlopecia totalisAlopecia universalisPercent changeAlopecia Tool (SALT) scorePatients age 18Primary end pointSerious adverse eventsMonths of treatmentCommon autoimmune disorderSeries of patientsScalp hair lossAdverse eventsClinical responseHigher percent changeAutoimmune disordersRetrospective studyEffective therapyRetrospective natureInclusion criteriaHair lossPotential respondersPatientsTool scoreTopical Ruxolitinib for the Treatment of Alopecia Universalis
Craiglow BG, Tavares D, King BA. Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatology 2016, 152: 490. PMID: 26649829, DOI: 10.1001/jamadermatol.2015.4445.Peer-Reviewed Original ResearchTofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
Dhayalan A, King BA. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis. JAMA Dermatology 2016, 152: 1-2. PMID: 26630079, DOI: 10.1001/jamadermatol.2015.3772.Peer-Reviewed Original Research
2014
Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
Craiglow BG, King BA. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis. Journal Of Investigative Dermatology 2014, 134: 2988-2990. PMID: 24940651, DOI: 10.1038/jid.2014.260.Peer-Reviewed Original Research